A recent study indicates that individuals who stop using popular GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass far faster than those who halt traditional diet and exercise programs.
Findings released in a major health publication demonstrates that while overweight individuals frequently drop substantial amounts of their total mass while undergoing treatment, the mass returns at an average rate of nearly a kilo each month upon discontinuation.
"People using such treatments should be aware of the risk of rapid weight regain when the therapy is stopped," warns researcher Dr. Susan Jebb.
That rate of recovery suggests a reversion to original weight in about a year and a half.
Analyzing Approaches
The analysis, which looked at 37 of trials involving over 9,000 of patients, contrasted the outcomes of the injectable medications with other pills.
The team emphasize that people who lose weight through dieting typically see a more gradual creep back—approximately 0.1 kg a month—after stopping.
Understanding the Rapid Rebound
Nutrition scientists believe the way of the injections is key to understanding the accelerated regain.
GLP-1 drugs imitate a body's own chemical called GLP-1, which helps regulate hunger.
"Artificially providing GLP-1 levels several times higher than normal could lead to the body to produce less of its endogenous GLP-1, and may also reduce responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication results in hunger is unsuppressed, making excessive eating far more likely."
A Chronic Issue?
The NHS recommend the injections for individuals with weight-linked health risks, alongside prescribed lifestyle changes.
A number of clinicians say that, considering the likelihood of relapse, the treatment is often life-long.
This opinion is supported by drug manufacturers, who say that the results "highlight the chronic nature of obesity," comparing it to managing diseases like high blood pressure.
Patient Testimonies
People who have discontinued the medication explain a intense resurgence of hunger.
"It was like something that goes on and you're instantly ravenous," recalled a patient.
The struggle is exacerbated if users have not adopted permanent lifestyle or habit modifications during treatment.
Growing Use
Figures show that millions of adults in the UK have used these injections in the past year, with interest remaining high.
- Use is more common among women compared to men.
- The 40s and 50s demographic shows the greatest usage rates.
- Many access the drugs through private healthcare rather than public health services.
Ultimately, experts stress that while GLP-1 drugs are effective tools for shedding pounds, they are not a permanent cure and lasting health benefits hinges on combined behavioural changes.
